REPL
Replimune Group, Inc.
$4.07
+21.86%
2026-05-08
About Replimune Group, Inc.
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Key Fundamentals
Forward P/E
-1.63
EPS (TTM)
$-3.44
ROE
-90.9%
Profit Margin
0.0%
Debt/Equity
36.26
Price/Book
1.28
Beta
0.12
Market Cap
$279.9M
Avg Volume (10D)
5.4M
Recent Breakout Signals
No recent breakout signals detected for REPL.
Recent Price Range (60 Days)
60D High
$9.10
60D Low
$1.50
Avg Volume
5.1M
Latest Close
$4.07
Get breakout alerts for REPL
Sign up for Breakout Scanner to receive daily notifications when REPL triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Replimune Group, Inc. (REPL) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors REPL daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. REPL operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.